Home / VCNX : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does VCNX make money? Does VCNX have pricing power? What's the Earnings Whisper? Will VCNX profit more as the business scales? What is VCNX's management track record? Is VCNX's current price justified?

Vaccinex, Inc.

$1.06 -$0.07 (-6.19%)

OTC · 14 Sep 2026 20:00 UTC

Previous Close

$1.05

Day Range

$1.05$1.06

Year Range

$0.31$1.5

Market Cap

2.84M

AVG Volume

1.75K

Trailing/Forward PE

-0.54/-

PEG ratio

-0

Dividend Yield

Next Earnings Date

2026-11-16

Primary Exchange

Other OTC

Revenue (USD)

VCNX Revenue (USD) by year
Period	Revenue (USD)
2024	601K
2023	184K
2022	100K
2021	1.75M
2020	100K
2019	523K
2018	724K
2017	90K

Net Income (USD)

VCNX Net Income (USD) by year
Period	Net Income (USD)
2024	-18.63M
2023	-20.23M
2022	-19.8M
2021	-22.38M
2020	-28.85M
2019	-31.86M
2018	-29.52M
2017	-18.72M

Operating Income (USD)

VCNX Operating Income (USD) by year
Period	Operating Income (USD)
2024	-18.73M
2023	-22.89M
2022	-19.91M
2021	-22.49M
2020	-28.33M
2019	-32.02M
2018	-27.28M
2017	-21.1M

EBITDA (USD)

VCNX EBITDA (USD) by year
Period	EBITDA (USD)
2024	-18.51M
2023	-19.75M
2022	-19.61M
2021	-21.39M
2020	-28.05M
2019	-31.72M
2018	-28.9M
2017	-17.35M

Cash Flows (USD)

VCNX Cash Flows (USD) by year
Period	Cash Flows (USD)
2024	-16.21M
2023	-17.3M
2022	-19.17M
2021	-25.35M
2020	-28.94M
2019	-30.79M
2018	-25.51M
2017	-21.45M

EPS (USD)

VCNX EPS (USD) by year
Period	EPS (USD)
2024	-10.48
2023	-69.03
2022	-99.79
2021	-165.67
2020	-327.66
2019	-533.91
2018	-811.91
2017	-689.86

Expenses (USD)

VCNX Expenses (USD) by year
Period	Expenses (USD)
2024	19.36M
2023	23.5M
2022	20.28M
2021	23.44M
2020	29.24M
2019	32.42M
2018	27.21M
2017	21.1M

Cash & Debt (USD)

VCNX Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2024	1.11M
2023	1.53M
2022	6.39M
2021	8.59M
2020	10.6M
2019	2.78M
2018	19.72M
2017	4.18M

Debt ratios

VCNX Debt ratios by year
Period	Debt ratios
2024	0.01
2023	0.01
2022	0.06
2021	0.07
2020	0.01

Margins

VCNX Margins by year
Period	Margins
2024	95.51%
2023	245.38%
2022	5%
2021	-426.74%
2020	-9832%
2019	-781.45%
2018	-42.68%
2017	-77.78%

Return on Capital

VCNX Return on Capital by year
Period	Return on Capital
2024	748.95%
2023	875.25%
2022	-381.24%
2021	-301.94%
2020	1104.48%
2019	1401.19%
2018	-192.4%
2017	1056.55%

Shares Outstanding

VCNX Shares Outstanding by year
Period	Shares Outstanding
2024	2.1M
2023	392.78K
2022	202.62K
2021	142.9K
2020	106.6K
2019	70.4K
2018	54.97K
2017	27.14K

Book Value Per Share (USD)

VCNX Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2024	-1.19
2023	-5.88
2022	25.63
2021	51.87
2020	-24.5
2019	-32.3
2018	279.08
2017	-65.29

Total Assets (USD)

VCNX Total Assets (USD) by year
Period	Total Assets (USD)
2024	2.6M
2023	3.63M
2022	7.98M
2021	9.84M
2020	11.7M
2019	4.6M
2018	22.03M
2017	5.58M

Employee Count

VCNX Employee Count by year
Period	Employee Count
2024	23
2023	37
2022	38
2021	39
2020	39
2019	45
2018	44

Free Cash Flow Yield

VCNX Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-728.49%
Sep 26	-735.43%
Sep 26	-1029.6%
Aug 26	-772.2%
Aug 26	-702%
Aug 26	-930.36%
Aug 26	-780%
Jul 26	-908.47%
Jul 26	-654.4%
Jul 26	-671.48%
Jul 26	-598.6%
Jul 26	-757.06%
Jun 26	-1002.85%
Jun 26	-695.67%
Jun 26	-764.55%
Jun 26	-772.2%
May 26	-772.2%
May 26	-772.2%
May 26	-702%
May 26	-764.55%
May 26	-772.2%
Apr 26	-735.43%
Apr 26	-772.2%
Apr 26	-772.2%
Apr 26	-772.2%
Mar 26	-648.9%
Mar 26	-869.59%
Mar 26	-1103.14%
Mar 26	-968.27%
Feb 26	-749.71%
Feb 26	-749.71%
Feb 26	-617.76%
Feb 26	-643.5%
Jan 26	-563.65%
Jan 26	-580.6%
Jan 26	-572%
Jan 26	-772.2%
Jan 26	-683.36%
Dec 25	-708.44%
Dec 25	-977.46%
Dec 25	-1544.08%
Dec 25	-1103.14%
Nov 25	-1103.3%
Nov 25	-1103.14%
Nov 25	-1105.51%
Nov 25	-1104.72%
Oct 25	-1223.57%
Oct 25	-878.79%
Oct 25	-1608.74%
Oct 25	-1514.11%
Oct 25	-1206.56%
Sep 25	-1043.51%
Sep 25	-1103.14%
Sep 25	-1218.94%
Sep 25	-1456.97%
Aug 25	-1544.39%
Aug 25	-772.2%
Aug 25	-986.08%
Aug 25	-1103.14%
Aug 25	-977.55%
Jul 25	-1087.6%
Jul 25	-848.57%
Jul 25	-821.49%
Jul 25	-1103.93%
Jun 25	-1057.8%
Jun 25	-1087.6%
Jun 25	-941.7%
Jun 25	-897.9%
May 25	-839.34%
May 25	-1135.58%
May 25	-742.5%
May 25	-1135.58%
May 25	-1152.53%
Apr 25	-858%
Apr 25	-1043.51%
Apr 25	-1118.38%
Apr 25	-1304.77%
Mar 25	-1043.82%
Mar 25	-1373.44%
Mar 25	-1057.92%
Mar 25	-841.79%
Feb 25	-711.69%
Feb 25	-760.06%
Feb 25	-899.84%
Feb 25	-767.51%
Jan 25	-652.39%
Jan 25	-669.11%
Jan 25	-724.87%
Jan 25	-680.75%
Jan 25	-652.39%
Dec 24	-718.22%
Dec 24	-646.99%
Dec 24	-212.16%
Dec 24	-200.22%
Nov 24	-207.11%
Nov 24	-216.26%
Nov 24	-247.74%
Nov 24	-279.82%
Nov 24	-294.05%
Oct 24	-256.64%

Price to Sales

VCNX Price to Sales by year
Period	Price to Sales
Sep 26	3.7
Sep 26	3.67
Sep 26	2.62
Aug 26	3.49
Aug 26	3.84
Aug 26	2.9
Aug 26	3.46
Jul 26	2.97
Jul 26	4.12
Jul 26	4.02
Jul 26	4.51
Jul 26	3.56
Jun 26	2.69
Jun 26	3.88
Jun 26	3.53
Jun 26	3.49
May 26	3.49
May 26	3.49
May 26	3.84
May 26	3.53
May 26	3.49
Apr 26	3.67
Apr 26	3.49
Apr 26	3.49
Apr 26	3.49
Mar 26	4.16
Mar 26	3.1
Mar 26	2.44
Mar 26	2.79
Feb 26	3.6
Feb 26	3.6
Feb 26	4.37
Feb 26	4.19
Jan 26	4.78
Jan 26	4.64
Jan 26	4.71
Jan 26	3.49
Jan 26	3.95
Dec 25	3.81
Dec 25	2.76
Dec 25	1.75
Dec 25	2.44
Nov 25	2.44
Nov 25	2.44
Nov 25	2.44
Nov 25	2.44
Oct 25	2.2
Oct 25	3.07
Oct 25	1.68
Oct 25	1.78
Oct 25	2.24
Sep 25	2.58
Sep 25	2.44
Sep 25	2.21
Sep 25	1.85
Aug 25	1.75
Aug 25	3.49
Aug 25	2.73
Aug 25	2.44
Aug 25	2.76
Jul 25	2.48
Jul 25	3.18
Jul 25	3.28
Jul 25	2.44
Jun 25	2.55
Jun 25	2.48
Jun 25	2.86
Jun 25	3
May 25	3.21
May 25	2.37
May 25	3.63
May 25	2.37
May 25	2.34
Apr 25	3.14
Apr 25	2.58
Apr 25	709.42
Apr 25	608.08
Mar 25	760.1
Mar 25	577.67
Mar 25	749.96
Mar 25	942.52
Feb 25	1114.81
Feb 25	1043.86
Feb 25	881.71
Feb 25	1033.73
Jan 25	1216.15
Jan 25	1185.75
Jan 25	1094.54
Jan 25	1165.48
Jan 25	1216.15
Dec 24	1104.67
Dec 24	1226.29
Dec 24	3739.67
Dec 24	3962.63
Nov 24	3830.88
Nov 24	3668.73
Nov 24	3202.53
Nov 24	-187.81
Nov 24	-178.72
Oct 24	-204.77

Price to Book

VCNX Price to Book by year
Period	Price to Book
Aug 24	2.29
Aug 24	2.61
Jul 24	3.36
Jul 24	3.55
Jul 24	3.29
Jul 24	3.32
Jun 24	3.24
Jun 24	3.05
Jun 24	3.43
Jun 24	3.71
May 24	3.39
May 24	2.7
May 24	2.77
Aug 23	5.38
Aug 23	5.58
Jul 23	5.79
Jul 23	6.41
Jul 23	6.41
Jul 23	7.44
Jun 23	7.44
Jun 23	7.24
Jun 23	7.86
Jun 23	9.51
Jun 23	8.68
May 23	8.48
May 23	8.27
May 23	3.28
May 23	2.87
Apr 23	2.95
Apr 23	3.28
Apr 23	3.52
Apr 23	3.28
Mar 23	3.28
Mar 23	2.77
Mar 23	2.77
Mar 23	2.9
Mar 23	3.44
Feb 23	3.11
Feb 23	3.44
Feb 23	3.85
Feb 23	3.98
Jan 23	4.05
Jan 23	3.98
Jan 23	4.32
Jan 23	4.32
Dec 22	4.32
Dec 22	4.59
Dec 22	4.73
Dec 22	4.39
Dec 22	4.39
Nov 22	2.97
Nov 22	3.51
Nov 22	2.27
Nov 22	2.16
Oct 22	2.19
Oct 22	1.85
Oct 22	2.04
Oct 22	2.23
Sep 22	1.89
Sep 22	1.82
Sep 22	3.03
Sep 22	2.76
Sep 22	3.03
Aug 22	3.75
Aug 22	3.78
Aug 22	2.6
Aug 22	2.44
Jul 22	2.48
Jul 22	2.65
Jul 22	2.79
Jul 22	2.79
Jul 22	2.46
Jun 22	2.7
Jun 22	2.53
Jun 22	3
Jun 22	3.19
May 22	3
May 22	2.84
May 22	4.82
May 22	5.1
Apr 22	5.34
Apr 22	5.06
Apr 22	4.98
Apr 22	5.26
Apr 22	5.22
Mar 22	3.6
Mar 22	3.78
Mar 22	3.11
Mar 22	2.82
Feb 22	3.76
Feb 22	3.26
Feb 22	4.59
Feb 22	4.27
Jan 22	2.93
Jan 22	2.69
Jan 22	2.9
Jan 22	2.9
Dec 21	2.69
Dec 21	3.37
Dec 21	3.42

No video analysis for this stock yet. Request one from our team.

News: VCNX

globenewswire.com · 8 Jul 2026

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026

ROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new biomarker data from its Phase 1b/2 trial to support plans for an enlarged randomized phase 2B SIGNAL-AD study of pepinemab for treatment for early Alzheimer's disease at the Alzheimer's Association International Conference in London, United Kingdom, on July 13, 2026.

AI Analysis

Vaccinex, Inc.

Video analysis: VCNX

News: VCNX

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026

Similar companies